Hyperaccelerated Award/Mechanisms in Immunomodulation Trials

The summary for the Hyperaccelerated Award/Mechanisms in Immunomodulation Trials grant is detailed below. This summary states who is eligible for the grant, how much grant money will be awarded, current and past deadlines, Catalog of Federal Domestic Assistance (CFDA) numbers, and a sampling of similar government grants. Verify the accuracy of the data FederalGrants.com provides by visiting the webpage noted in the Link to Full Announcement section or by contacting the appropriate person listed as the Grant Announcement Contact. If any section is incomplete, please visit the website for the National Institutes of Health, which is the U.S. government agency offering this grant.

Hyperaccelerated Award/Mechanisms in Immunomodulation Trials: - This RFA invites R01 applications for mechanistic studies in clinical trials of: immunomodulatory interventions for immune system mediated diseases, including, but not limited to: asthma and allergic diseases; graft failure in solid organ, cell, tissue and stem cell transplantation; and chronic inflammatory, autoimmune, and immunodeficiency diseases; preventative and therapeutic, vaccines for non-HIV/AIDS infectious diseases, including NIAID Category A, B, and C agents of bioterrorism and emerging/re-emerging infectious diseases. - This Request for Applications (RFA) is a renewal with modifications of RFA-AI-04-001 (http://grants.nih.gov/grants/guide/rfa-files/RFA-AI-04-001.html). - In order to review and confer awards to grant applications received in response to this RFA in a timely fashion, without delay of the parent clinical trial, applications submitted in response to the RFA will be subject to a hyperaccelerated review/award process. Highly meritorious applications selected for funding under this RFA may receive their awards as early as thirteen weeks after the application receipt date. Holidays and other circumstances may alter this schedule slightly. - The National Institute of Allergy and Infectious Diseases (NIAID), the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), the National Institute of Neurological Disorders and Stroke (NINDS), and National Institute of Arthritis and Musculoskeletal and Skin Diseases of the National Institutes of Health (NIH) intend to commit $1.6 million in Fiscal Year 2006 to fund four to five applications. The total requested project period for an application submitted in response to this RFA may not exceed four years. - Eligible organizations include for-profit or non-profit organizations, public or private institutions (e.g., universities, colleges, hospitals), units of state and local governments, and eligible agencies of the Federal government. Both domestic and foreign institutions are eligible to apply. - Eligible principal investigators include any individual with the skills, knowledge, and resources necessary to carry out the proposed research. Individuals from underrepresented racial and ethnic groups as well as individuals with disabilities are encouraged to apply for NIH programs. - Only under extraordinary circumstances and with the approval of the participating ICs would an applicant be allowed to submit more than one application per fiscal year (October 1 September 30) as a Principal Investigator. Amended applications will ONLY be accepted for Hyperaccelerated Review/Award if invited by the sponsoring NIH Institutes. - See Section IV.1 for application materials. - Applications must be prepared using the PHS 398 research grant application instructions and forms (rev. 9/2004); The PHS 398 document is available at http://grants.nih.gov/grants/funding/phs398/phs398.html in an interactive format. For further assistance contact GrantsInfo, Telephone (301) 435-0714, Email: [email protected]. - Telecommunications for the hearing impaired is available at: TTY 301-451-0088.